423 related articles for article (PubMed ID: 34372513)
1. Antivirals against the Chikungunya Virus.
Battisti V; Urban E; Langer T
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372513
[TBL] [Abstract][Full Text] [Related]
2. 4'-Fluorouridine inhibits alphavirus replication and infection
Yin P; May NA; Lello LS; Fayed A; Parks MG; Drobish AM; Wang S; Andrews M; Sticher Z; Kolykhalov AA; Natchus MG; Painter GR; Merits A; Kielian M; Morrison TE
mBio; 2024 Jun; 15(6):e0042024. PubMed ID: 38700353
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Inhibitors of Chikungunya Virus: Mechanisms of Action and Antiviral Drug Resistance.
Kovacikova K; van Hemert MJ
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928738
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.
Bouma EM; van de Pol DPI; Sanders ID; Rodenhuis-Zybert IA; Smit JM
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321803
[TBL] [Abstract][Full Text] [Related]
5. Current Strategies for Inhibition of Chikungunya Infection.
Subudhi BB; Chattopadhyay S; Mishra P; Kumar A
Viruses; 2018 May; 10(5):. PubMed ID: 29751486
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
Ashbrook AW; Lentscher AJ; Zamora PF; Silva LA; May NA; Bauer JA; Morrison TE; Dermody TS
mBio; 2016 May; 7(3):. PubMed ID: 27222471
[TBL] [Abstract][Full Text] [Related]
7. Beyond Members of the
Ferreira AC; Reis PA; de Freitas CS; Sacramento CQ; Villas Bôas Hoelz L; Bastos MM; Mattos M; Rocha N; Gomes de Azevedo Quintanilha I; da Silva Gouveia Pedrosa C; Rocha Quintino Souza L; Correia Loiola E; Trindade P; Rangel Vieira Y; Barbosa-Lima G; de Castro Faria Neto HC; Boechat N; Rehen SK; Brüning K; Bozza FA; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455237
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Strategies Against Chikungunya Virus.
Abdelnabi R; Neyts J; Delang L
Methods Mol Biol; 2016; 1426():243-53. PubMed ID: 27233277
[TBL] [Abstract][Full Text] [Related]
9. Chikungunya virus drug discovery: still a long way to go?
Pérez-Pérez MJ; Delang L; Ng LFP; Priego EM
Expert Opin Drug Discov; 2019 Sep; 14(9):855-866. PubMed ID: 31177861
[No Abstract] [Full Text] [Related]
10. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses.
Varghese FS; Kaukinen P; Gläsker S; Bespalov M; Hanski L; Wennerberg K; Kümmerer BM; Ahola T
Antiviral Res; 2016 Feb; 126():117-24. PubMed ID: 26752081
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapeutics for chikungunya virus.
Ghildiyal R; Gabrani R
Expert Opin Ther Pat; 2020 Jun; 30(6):467-480. PubMed ID: 32249636
[No Abstract] [Full Text] [Related]
12. Chikungunya virus infections: time to act, time to treat.
Abdelnabi R; Neyts J; Delang L
Curr Opin Virol; 2017 Jun; 24():25-30. PubMed ID: 28414993
[TBL] [Abstract][Full Text] [Related]
13. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms.
Ho YJ; Liu FC; Yeh CT; Yang CM; Lin CC; Lin TY; Hsieh PS; Hu MK; Gong Z; Lu JW
Antiviral Res; 2018 Nov; 159():134-142. PubMed ID: 30300716
[TBL] [Abstract][Full Text] [Related]
14. The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling.
Varghese FS; Thaa B; Amrun SN; Simarmata D; Rausalu K; Nyman TA; Merits A; McInerney GM; Ng LFP; Ahola T
J Virol; 2016 Nov; 90(21):9743-9757. PubMed ID: 27535052
[TBL] [Abstract][Full Text] [Related]
15. Antivirals against Chikungunya Virus: Is the Solution in Nature?
Martins DOS; Santos IA; de Oliveira DM; Grosche VR; Jardim ACG
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121393
[TBL] [Abstract][Full Text] [Related]
16. Activity of andrographolide against chikungunya virus infection.
Wintachai P; Kaur P; Lee RC; Ramphan S; Kuadkitkan A; Wikan N; Ubol S; Roytrakul S; Chu JJ; Smith DR
Sci Rep; 2015 Sep; 5():14179. PubMed ID: 26384169
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of nobiletin against chikungunya virus in vitro.
Lin SC; Chen MC; Li S; Lin CC; Wang TT
Antivir Ther; 2017; 22(8):689-697. PubMed ID: 28406093
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
[TBL] [Abstract][Full Text] [Related]
19. In silico identification of chikungunya virus replication inhibitor validated using biochemical and cell-based approaches.
Chaudhary M; Kumar A; Bala Sharma K; Vrati S; Sehgal D
FEBS J; 2024 Jun; 291(12):2656-2673. PubMed ID: 38303163
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission.
Wang YM; Lu JW; Lin CC; Chin YF; Wu TY; Lin LI; Lai ZZ; Kuo SC; Ho YJ
Antiviral Res; 2016 Nov; 135():81-90. PubMed ID: 27742486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
